HeLa Cells: Continuous Culture and Henrietta Lacks

In 1951, Henrietta Lacks received diagnosis and treatment for cervical cancer at Johns Hopkins Hospital in Baltimore, Maryland. She was an African American woman and the mother of five children. Tumor tissue removed during treatment was sent to George Gey's laboratory and became the source of the cell line later called HeLa, named from the opening letters of her first and last names. Lacks died that year, while the cells in the laboratory continued multiplying.

Permission for treatment must be distinguished from consent to research. The treatment forms Lacks signed did not inform her that tissue would be continuously cultured and distributed, and she did not make an informed decision to donate it for research. Simply calling her a voluntary “donor” obscures this essential fact. Hospital care, research sampling and later commercial use were separate processes; they cannot substitute for one another, nor can one institution's actions automatically be attributed to all participants.

References: [2] [3] [4]

Gey and colleagues had long tried to maintain cells outside the human body, but many earlier samples soon died. Lacks's tumor cells continued proliferating under appropriate nutritional and culture conditions. Laboratory worker Mary Kubicek helped process and culture the samples. In a 1952 report, Gey, Ward Coffman and Kubicek discussed in-vitro growth of cervical carcinoma and normal epithelium, recording that a cancer-cell strain had been maintained in roller tubes for almost a year.

Their medium included chicken plasma, bovine embryo extract and human cord serum, showing the dependence of the achievement on specific culture conditions and skilled handling. “Immortal” means that the cell population can be continuously passaged, not that each cell lives forever or that the patient herself continues unchanged. Tumor cells' abnormal proliferation made them convenient research material, but also meant they could not represent every healthy human tissue without examination.

References: [1] [2]

Gey supplied cells to other researchers, allowing laboratories to repeat studies using comparable material. As culture, storage and transport developed, supply no longer depended entirely on obtaining fresh human tissue each time. A cell line that could be divided and expanded changed experimental design: researchers could establish treatment and control groups simultaneously, compare effects of drugs, radiation or viruses, and have others check the results.

HeLa cells participated in poliovirus and vaccine-related research and were later used in cancer, genetics and studies of various infections. Their contribution was as an experimental platform; it should not be described as though one cell type alone invented these treatments. Research uses, the hospital's initial free distribution and later commercial production and sales require separate accounts. Freely circulating material does not automatically settle what recognition and participation its source person should receive.

References: [2] [3]

For years, the cell name circulated in papers and laboratories while researchers knew little of Lacks's life or her family's experiences. More than twenty years after her death, relatives gradually learned that her cells were still being used and faced difficult technical language, media attention and requests for research samples. Rebecca Skloot's 2010 book combined investigation and family accounts to bring the experiences of Henrietta, her daughter Deborah and others into public discussion.

This history raises more than the question of whether a signature procedure was complete. How research information is explained, whether relatives can learn where material goes, and how scientific credit and benefits are distributed all concern lasting trust. Describing the absence of today's tissue-research systems helps explain historical conditions, but an institutional gap is not evidence of patient consent, and the importance of research results does not erase effects on the family.

References: [2] [3]

In 2013, publication of the HeLa whole-genome sequence renewed controversy. Although altered by cancer and long-term culture, the sequence could still reveal genetic information relevant to relatives. After consultation with the Lacks family, the U.S. National Institutes of Health established controlled access for the relevant whole-genome data. Researchers had to state their purposes and accept data-use conditions; two family representatives sat on the group reviewing access requests, and publications had to include a prescribed acknowledgment of Lacks and her family.

These arrangements addressed access to and use of particular genomic data. They did not give the family approval over every HeLa experiment worldwide, nor did they retrospectively obtain consent for 1951. They reflected a change in the object of research governance, from culturable cells to data that can be copied and circulated. The scientific value of continuous culture and the dignity of the person from whom it originated are facts that must be explained together in this history.

References: [3] [4]